HUTCHMED's Savolitinib Hits Primary Endpoint in Gastric Cancer Trial
Event summary
- HUTCHMED's savolitinib met primary endpoint in Phase II gastric cancer trial, with a 32.3% ORR.
- Data supported NDA submission to China's NMPA, which granted priority review in December 2025.
- Additional data on fruquintinib and surufatinib across multiple tumor indications to be presented at ASCO 2026.
The big picture
HUTCHMED's positive Phase II data for savolitinib positions it as a potential new treatment option for MET-amplified gastric cancer, a niche but underserved patient population. The company is expanding its clinical footprint with fruquintinib and surufatinib across multiple tumor types, aligning with the broader trend of precision oncology and combination therapies in cancer treatment.
What we're watching
- Regulatory Momentum
- Whether the NMPA's priority review for savolitinib will lead to expedited approval in China.
- Clinical Pipeline Depth
- The pace at which HUTCHMED can translate ASCO data into additional regulatory filings or partnerships.
- Competitive Positioning
- How savolitinib's efficacy compares to existing MET inhibitors in the gastric cancer space.